Clinical Trial: NCT04665765
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | City of Hope Medical Center |
| Information Provided By: | City of Hope Medical Center |
| Last Update Posted: | 2026-09-11 |
Study Overview
Brief Summary
This phase II trial studies the effect of polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide as initial salvage therapy in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79b positive cancer cells in a targeted way and delivers vedotin to kill them. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with immunotherapy may kill more cancer cells in patients with diffuse large B-cell lymphoma.
Official Title
Conditions
Intervention / Treatment
- Drug: Carboplatin
- Drug: Etoposide
- Drug: Ifosfamide
- Drug: Polatuzumab Vedotin
- Biological: Rituximab
Other Study ID Numbers
- 20148
- NCI-2020-08524
- 20148
- P30CA033572
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | City of Hope Medical Center |
| Information Provided By: | City of Hope Medical Center |
| Last Update Posted: | 2026-09-11 |
Study Overview
Brief Summary
This phase II trial studies the effect of polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide as initial salvage therapy in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79b positive cancer cells in a targeted way and delivers vedotin to kill them. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with immunotherapy may kill more cancer cells in patients with diffuse large B-cell lymphoma.
Official Title
Conditions
Intervention / Treatment
- Drug: Carboplatin
- Drug: Etoposide
- Drug: Ifosfamide
- Drug: Polatuzumab Vedotin
- Biological: Rituximab
Other Study ID Numbers
- 20148
- NCI-2020-08524
- 20148
- P30CA033572